We are 4,6-Dichloro-2-(propylthio)pyrimidin-5-amine CAS:145783-15-9 manufacturer and supplier in China, Pls send inquiry of to email@example.com of visit www.nbinno.com our official website should you have any interests
Product Name: 4,6-Dichloro-2-(propylthio)pyrimidin-5-amine
Synonym: Intermediate of Ticagrelor; 5-Amino-4,6-dichloro-2-(propylthio)pyrimidine; 4,6-dichloro-2-(propylsulfanyl)-5-pyriMidinaMine
Cas No.: 145783-15-9
EINECS No.: 808-051-8
HS Code: 2942000000
UN No.: 1759
Hazard class: 8 categories
Packing level: Class III
|Items of Analysis||Standard of Analysis||Test Results|
|Appearance|| Yellow to yellowish brown oily
matter or solid
|Conclusion||Conforms to Factory Standard|
Intermediate of Ticagrelor.
25 kg/barrel, can also be packaged according to customer requirements.
Store in a cool, ventilated warehouse.
Keep away from fire and heat.
The temperature should not exceed 37 °C.
Related News: The iLet is designed to function as three medical devices in one. It can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a bihormonal bionic pancreas using insulin and glucagon.HC Blue 14 CAS:99788-75-7 China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement.2-(4-nitrophenyl)ethanamine,hydrochloride CAS:29968-78-3 Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.Biphenyl-3-boronic acid CAS:5122-95-2 Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).